World's Best Scientists 2026 revealed!
Award Badge
Medicine
Germany
2026

D-Index & Metrics

Medicine

D-Index
139
Citations
123798
World Ranking
1715
National Ranking
85

Peter R. Galle publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Peter R. Galle sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 1,257 publications — 97th percentile

97% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Peter R. Galle D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Peter R. Galle sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 139 D-Index — 92nd percentile

92% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • 2026 - Research.com Medicine in Germany Leader Award
  • 2023 - Research.com Medicine in Germany Leader Award

Overview

What is he best known for?

The fields of study he is best known for:

  • Internal medicine
  • Gene
  • Cancer

His primary areas of study are Immunology, Internal medicine, Pathology, Cancer research and Gastroenterology. His Internal medicine study integrates concerns from other disciplines, such as Surgery and Oncology. His biological study spans a wide range of topics, including Cancer, Colorectal cancer, Intestinal mucosa and In vivo.

His Cancer research research is multidisciplinary, incorporating perspectives in Cell growth, Cancer cell, Interleukin 6, Apoptosis and Signal transduction. His Gastroenterology study combines topics from a wide range of disciplines, such as Clinical endpoint, Prospective cohort study, Phases of clinical research and Adenocarcinoma. The study incorporates disciplines such as Proinflammatory cytokine, Molecular biology and Immune system in addition to Cytokine.

His most cited work include:

  • Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. (1072 citations)
  • p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias (682 citations)
  • Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. (410 citations)

What are the main themes of his work throughout his whole career to date?

The scientist’s investigation covers issues in Internal medicine, Gastroenterology, Immunology, Hepatocellular carcinoma and Cancer research. His research integrates issues of Surgery and Oncology in his study of Internal medicine. His study connects Liver transplantation and Gastroenterology.

Many of his studies on Immunology apply to Virology as well. His Hepatocellular carcinoma study incorporates themes from Carcinoma and Ramucirumab. Peter R. Galle focuses mostly in the field of Cancer research, narrowing it down to matters related to Cancer and, in some cases, Pathology.

He most often published in these fields:

  • Internal medicine (40.17%)
  • Gastroenterology (20.08%)
  • Immunology (17.70%)

What were the highlights of his more recent work (between 2018-2021)?

  • Internal medicine (40.17%)
  • Gastroenterology (20.08%)
  • Hepatocellular carcinoma (15.42%)

In recent papers he was focusing on the following fields of study:

Internal medicine, Gastroenterology, Hepatocellular carcinoma, In patient and Oncology are his primary areas of study. His study in Ramucirumab, Cirrhosis, Cohort, Fatty liver and Liver disease falls within the category of Internal medicine. His Gastroenterology research incorporates themes from Fibrosis, Prospective cohort study, Liver transplantation and Disease.

His Hepatocellular carcinoma research is multidisciplinary, relying on both Carcinoma, Proportional hazards model and First line treatment. He interconnects Bevacizumab, Open label, Atezolizumab and Biomarker in the investigation of issues within Oncology. The concepts of his Sorafenib study are interwoven with issues in Clinical trial, Progression-free survival and Systemic therapy.

Between 2018 and 2021, his most popular works were:

  • Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. (410 citations)
  • IMbrave150: Efficacy and safety results from a ph III study evaluating atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC) (97 citations)
  • Biology and significance of alpha-fetoprotein in hepatocellular carcinoma. (51 citations)

In his most recent research, the most cited papers focused on:

  • Internal medicine
  • Gene
  • Cancer

His main research concerns Internal medicine, Hepatocellular carcinoma, In patient, Gastroenterology and Oncology. His research links Resection with Internal medicine. The Hepatocellular carcinoma study combines topics in areas such as Bevacizumab, Carcinoma and First line treatment.

His work in Gastroenterology addresses subjects such as Ramucirumab, which are connected to disciplines such as Hazard ratio, Safety profile and Elevated alpha-fetoprotein. His Oncology research is multidisciplinary, incorporating elements of Open label, Scoring system, Neuroblastoma RAS viral oncogene homolog, Biomarker and Primary tumor. His Pathology research includes themes of Liver injury and Liver function tests.

Best Publications

  • Sorafenib in Advanced Hepatocellular Carcinoma

    Josep M. Llovet;Sergio Ricci;Vincenzo Mazzaferro;Philip Hilgard

  • EASL-EORTC clinical practice guidelines : management of hepatocellular carcinoma

    Peter R. Galle;Alejandro Forner;Josep M. Llovet;Vincenzo Mazzaferro

  • Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

    Richard S Finn;Shukui Qin;Masafumi Ikeda;Peter R Galle

  • BCLC strategy for prognosis prediction and treatment recommendation Barcelona Clinic Liver Cancer (BCLC) staging system. The 2022 update.

    M. Reig;A. Forner;J. Rimola;J. Ferrer-Fábrega

  • Simplified criteria for the diagnosis of autoimmune hepatitis

    Elke M. Hennes;Mikio Zeniya;Albert. J. Czaja;Albert Parés

  • Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo.

    R Atreya;J Mudter;S Finotto;J Müllberg

  • Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.

    Andrew X Zhu;Yoon-Koo Kang;Chia-Jui Yen;Richard S Finn

  • Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25- T cells through Foxp3 induction and down-regulation of Smad7.

    Massimo C. Fantini;Christoph Becker;Giovanni Monteleone;Francesco Pallone

  • Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma

    John Bridgewater;Peter R. Galle;Shahid A. Khan;Josep M. Llovet

  • Confocal laser endoscopy for diagnosing intraepithelial neoplasias and colorectal cancer in vivo

    Ralf Kiesslich;Juergen Burg;Michael Vieth;Janina Gnaendiger

  • Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells--a mechanism of immune evasion?

    Susanne Strand;Walter J. Hofmann;Hubert Hug;Martina Müller

  • p53 Activates the CD95 (APO-1/Fas) Gene in Response to DNA Damage by Anticancer Drugs

    Martina Müller;Sylvia Wilder;Detlev Bannasch;David Israeli

  • Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening

    Vlad Ratziu;Vlad Ratziu;Stephen A. Harrison;Sven Francque;Pierre Bedossa

  • Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis.

    Ralf Kiesslich;Johannes Fritsch;Martin Holtmann;Heinz H. Koehler

  • CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes.

    Imke Tiede;Gerhard Fritz;Susanne Strand;Daniela Poppe

  • p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias.

    Hartmut Döhner;Konstanze Fischer;Martin Bentz;Katrin Hansen

  • Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage.

    Peter R. Galle;Walter J. Hofmann;Henning Walczak;Heinz Schaller

  • TGF-β Suppresses Tumor Progression in Colon Cancer by Inhibition of IL-6 trans-Signaling

    Christoph Becker;Massimo C. Fantini;Christoph Schramm;Hans A. Lehr

  • Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53.

    Martina Müller;Susanne Strand;Hubert Hug;Eva Maria Heinemann

  • Development of Spontaneous Airway Changes Consistent with Human Asthma in Mice Lacking T-bet

    Susetta Finotto;Markus F. Neurath;Jonathan N. Glickman;Shixin Qin

Frequent Co-Authors

Markus F. Neurath
Markus F. Neurath University of Erlangen-Nuremberg
Joachim Mössner
Joachim Mössner Leipzig University
Jörn M. Schattenberg
Jörn M. Schattenberg Johannes Gutenberg University of Mainz
Ansgar W. Lohse
Ansgar W. Lohse Universität Hamburg
Richard S. Finn
Richard S. Finn University of California, Los Angeles
Masatoshi Kudo
Masatoshi Kudo Kindai University
Andrew X. Zhu
Andrew X. Zhu Harvard University
Dennis Strand
Dennis Strand Johannes Gutenberg University of Mainz
Stefan Wirtz
Stefan Wirtz University of Erlangen-Nuremberg
Josep M. Llovet
Josep M. Llovet University of Barcelona

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Interested in exploring alternative healthcare careers or supplementing your pre-medical education? Several related online degrees and flexible pathways can help you launch or enhance a career in the health sector.

Nursing is a rewarding option, and students can now find nursing schools that don't require teas or hesi. These programs are ideal for those who wish to avoid standardized entrance exams and start their hands-on medical training more quickly.

If you're interested in leadership roles, consider exploring healthcare administration degrees. These accelerated programs allow you to specialize in management and lead health organizations.

For current registered nurses, there are convenient adn to fnp bridge programs. These pathways enable RNs to advance quickly to a Master’s degree and become Family Nurse Practitioners.

Another growing field is nutrition and wellness. The best online food science degree options equip students for careers in dietetics, food safety, and public health.

These online and accelerated programs provide flexible alternatives for those passionate about healthcare but seeking different or faster career routes outside traditional medical school.

Best Scientists Citing Peter R. Galle

Trending Scientists

Recently Published Articles